AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

INDUCTION OF ALTERNATIVE APOPTOTIC PATHWAY BY INHIBITION OF CHK1 IN CANCER CELLS HARBORING P53 AND BCL2 MUTATIONS

Technology Benefits

Resistance, chemo- and radiotherapy

Technology Application

combinations of CHK1 inhibitors with genotoxic stress may be more effective in patients with defective p53 genotype. In addition, monitoring of Caspase 2 activation in tumor samples may be prognostic factor for patient response for such combination therapy.

Detailed Technology Description

The Dana-Farber investigators discovered a novel approach to kill cancer cells that are otherwise resistant to conventional therapies due to mutations in pro-apoptotic (p53) or pro-survival (BCL2) pathway components. This death mechanism is induced when radio- or chemotherapy are combined with inhibitors targeting cell cycle check point molecule CHK1. Such treatment triggers a caspase-2-dependent apoptotic program that bypasses p53 deficiency and excess Bcl-2. The discovery was made by screening in p53 mutant zebrafish embryos and re-evaluated in human cancer cells.

Country/Region

USA

For more information, please click Here